VirtualScopics's EPS (Basic) for the
three
months ended in Dec. 2015 was $0.01.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2015 was $-0.41.
VirtualScopics Earnings per Share (Diluted) Historical Data
The historical data trend for VirtualScopics's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of VirtualScopics's Earnings per Share (Diluted)
For the Medical Devices subindustry, VirtualScopics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VirtualScopics's PE Ratio Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, VirtualScopics's PE Ratio distribution charts can be found below:
* The bar in red indicates where VirtualScopics's PE Ratio falls into.
VirtualScopics Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
VirtualScopics's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2015 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.41
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
VirtualScopics (NAS:VSCP) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
VirtualScopics Earnings per Share (Diluted) Related Terms
Thank you for viewing the detailed overview of VirtualScopics's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.
VirtualScopics (VirtualScopics) Business Description
VirtualScopics Inc. is a provider of quantitative imaging for clinical trials serving the pharmaceutical, biotechnology and medical device industries. The Company has developed a software platform for analysis and modeling of both structural and functional medical images. This platform provides information about the biological activity of drugs and devices in clinical trial patients. VirtualScopics is an imaging core lab providing central reads and quantitative imaging solutions for drug and medical device clinical trials for the areas of oncology, rheumatoid arthritis, osteoarthritis, neurology, and cardiovascular studies utilizing MRI, PET, CT, Ultrasound, and X-ray imaging modalities. The Company's image-based measurement and visualization tools enable automated and reproducible measurement of minute changes that occur in anatomic structures in musculoskeletal, oncological, cardiological and neurological diseases. The Company's image analysis provides a degree of accuracy and reproducibility that cannot be duplicated by manual techniques. The Company's quantitative imaging replaces subjective evaluation. It has developed a suite of patented semi-automated tools for the identification and measurement of carotid plaques. Evaluating diseases such as multiple sclerosis (MS), epilepsy, and Alzheimer's requires the identification and measurement of neurological structures and lesions. The Company's competition is largely comprised of a limited number of university research centers that are working on developing the next generation of image analysis tools. The Company's main customers are Novartis, Merck Serono and Amgen. The Company's main competitors are clinical research organizations (CROs) providing clinical trial services to pharmaceutical companies. Healthcare in the United States is heavily regulated by the federal government, and by state and local governments.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VSCP has been successfully added to your 